Abbott Laboratories (ABT) EBT (2009 - 2026)

Abbott Laboratories has disclosed EBT across 18 years of filings, most recently posting $1.4 billion for Q1 2026.

• EBT for Q1 2026 came in at $1.4 billion, down 18.5% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.1 billion (up 10.63% YoY), and the FY2025 annual result was $8.5 billion, up 20.72% from the prior year.
• EBT came in at $1.4 billion for Q1 2026 at Abbott Laboratories, down from $2.4 billion in the prior quarter.
• In the past five years, EBT ranged from a high of $2.9 billion in Q1 2022 to a low of $1.3 billion in Q4 2022.
• The 5-year median for EBT is $1.8 billion (2025), against an average of $1.9 billion.
• Across the five-year window, EBT soared 74.48% in 2022 and tumbled 45.69% in 2023, its largest moves.
• Abbott Laboratories' EBT stood at $1.3 billion in 2022, then jumped by 35.98% to $1.8 billion in 2023, then climbed by 13.09% to $2.0 billion in 2024, then advanced by 16.16% to $2.4 billion in 2025, then plunged by 38.55% to $1.4 billion in 2026.
• The last three EBT figures came in at $1.4 billion (Q1 2026), $2.4 billion (Q4 2025), and $2.2 billion (Q3 2025), per Business Quant data.